La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture

Identifieur interne : 000B85 ( PascalFrancis/Corpus ); précédent : 000B84; suivant : 000B86

Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture

Auteurs : Sophie Callier ; Maryvonne Le Saux ; Anne-Marie Lhiaubet ; Thérèse Di Paolo ; William Rostene ; Didier Pelaprat

Source :

RBID : Pascal:02-0295171

Descripteurs français

English descriptors

Abstract

Recent findings suggest that gonadal steroid hormones are neuroprotective and may provide clinical benefits in delaying the development of Parkinson's disease. In this report we investigated the ability of oestradiol to protect mesencephalic dopaminergic neurones cultured in serum-free or serum-supplemented medium from toxicity induced by 6-hydroxy-dopamine or 1-methyl-4-phenylpyridinium ion (MPP+). The efficiency of both toxins and oestradiol was evaluated by tyrosine hydroxylase (TH) immunocytochemistry, [3H]dopamine ([3H]DA) uptake, length of dopaminergic processes and lactate dehydrogenase (LDH) release measurement. In cultures grown in serum-supplemented medium, a 2-h pre-treatment with high concentrations (10-100 μM) of 17β-oestradiol or 17α-oestradiol, the stereoisomer with weak oestrogenic activity, protected both dopaminergic and non-dopaminergic neurones from toxicity induced by 6-hydroxydopamine (6-OHDA; 40 or 100 μM) and by the high MPP+ concentrations (50 μM) necessary to obtain significant neuronal death under those culture conditions. At these concentrations, MPP+ was no longer selective for dopaminergic neurones but affected all cells present in the culture. In contrast, the hormonal treatments did not protect against selective degeneration of dopaminergic neurones induced by lower MPP+ concentrations (below 10 μM), related to inhibition of complex I of respiratory chain. In cultures grown in serum-free medium, oestradiol concentrations higher than 1 μM induced neuronal degeneration and no protection against 6-OHDA or MPP+ toxicity was observed at lower concentrations of the steroid. The neuroprotective effects of 17a- or 17p-oestradiol evidenced in this model might be due to the antioxidant properties of these compounds. However, other non-genomic effects of the steroids cannot be excluded.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0022-3042
A02 01      @0 JONRA9
A03   1    @0 J. neurochem.
A05       @2 80
A06       @2 2
A08 01  1  ENG  @1 Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture
A11 01  1    @1 CALLIER (Sophie)
A11 02  1    @1 LE SAUX (Maryvonne)
A11 03  1    @1 LHIAUBET (Anne-Marie)
A11 04  1    @1 DI PAOLO (Thérèse)
A11 05  1    @1 ROSTENE (William)
A11 06  1    @1 PELAPRAT (Didier)
A14 01      @1 Unité 339 INSERM. Hopital saint Antoine @2 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut.
A14 02      @1 Oncology and Molecular Endocrinology Research Center, Laval University Medical Center @2 Sainte Foy, Québec @3 CAN @Z 1 aut. @Z 4 aut.
A20       @1 307-316
A21       @1 2002
A23 01      @0 ENG
A43 01      @1 INIST @2 4037 @5 354000102175200110
A44       @0 0000 @1 © 2002 INIST-CNRS. All rights reserved.
A45       @0 1 p.3/4
A47 01  1    @0 02-0295171
A60       @1 P
A61       @0 A
A64 01  1    @0 Journal of neurochemistry
A66 01      @0 USA
C01 01    ENG  @0 Recent findings suggest that gonadal steroid hormones are neuroprotective and may provide clinical benefits in delaying the development of Parkinson's disease. In this report we investigated the ability of oestradiol to protect mesencephalic dopaminergic neurones cultured in serum-free or serum-supplemented medium from toxicity induced by 6-hydroxy-dopamine or 1-methyl-4-phenylpyridinium ion (MPP+). The efficiency of both toxins and oestradiol was evaluated by tyrosine hydroxylase (TH) immunocytochemistry, [3H]dopamine ([3H]DA) uptake, length of dopaminergic processes and lactate dehydrogenase (LDH) release measurement. In cultures grown in serum-supplemented medium, a 2-h pre-treatment with high concentrations (10-100 μM) of 17β-oestradiol or 17α-oestradiol, the stereoisomer with weak oestrogenic activity, protected both dopaminergic and non-dopaminergic neurones from toxicity induced by 6-hydroxydopamine (6-OHDA; 40 or 100 μM) and by the high MPP+ concentrations (50 μM) necessary to obtain significant neuronal death under those culture conditions. At these concentrations, MPP+ was no longer selective for dopaminergic neurones but affected all cells present in the culture. In contrast, the hormonal treatments did not protect against selective degeneration of dopaminergic neurones induced by lower MPP+ concentrations (below 10 μM), related to inhibition of complex I of respiratory chain. In cultures grown in serum-free medium, oestradiol concentrations higher than 1 μM induced neuronal degeneration and no protection against 6-OHDA or MPP+ toxicity was observed at lower concentrations of the steroid. The neuroprotective effects of 17a- or 17p-oestradiol evidenced in this model might be due to the antioxidant properties of these compounds. However, other non-genomic effects of the steroids cannot be excluded.
C02 01  X    @0 002B02B10
C03 01  X  FRE  @0 Mésencéphale @5 01
C03 01  X  ENG  @0 Midbrain @5 01
C03 01  X  SPA  @0 Mesencéfalo @5 01
C03 02  X  FRE  @0 Neurone dopaminergique @5 02
C03 02  X  ENG  @0 Dopaminergic neuron @5 02
C03 02  X  SPA  @0 Neurona dopaminérgica @5 02
C03 03  X  FRE  @0 Neurotoxine @5 03
C03 03  X  ENG  @0 Neurotoxin @5 03
C03 03  X  SPA  @0 Neurotoxina @5 03
C03 04  X  FRE  @0 Mort cellulaire @5 04
C03 04  X  ENG  @0 Cell death @5 04
C03 04  X  SPA  @0 Muerte celular @5 04
C03 05  X  FRE  @0 Neuroprotecteur @5 05
C03 05  X  ENG  @0 Neuroprotective agent @5 05
C03 05  X  SPA  @0 Neuroprotector @5 05
C03 06  X  FRE  @0 17α-Oestradiol @2 NK @5 06 @6 «17α»-Oestradiol
C03 06  X  ENG  @0 17α-Estradiol @2 NK @5 06 @6 «17α-»Estradiol
C03 06  X  SPA  @0 17α-Estradiol @2 NK @5 06 @6 «17α»-Estradiol
C03 07  X  FRE  @0 17β-Oestradiol @2 NK @5 07 @6 «17β»-Oestradiol
C03 07  X  ENG  @0 17β-Estradiol @2 NK @5 07 @6 «17β»-Estradiol
C03 07  X  SPA  @0 17β-Estradiol @2 NK @5 07 @6 «17β»-Estradiol
C03 08  X  FRE  @0 Antioxydant @5 08
C03 08  X  ENG  @0 Antioxidant @5 08
C03 08  X  SPA  @0 Antioxidante @5 08
C03 09  X  FRE  @0 In vitro @5 10
C03 09  X  ENG  @0 In vitro @5 10
C03 09  X  SPA  @0 In vitro @5 10
C03 10  X  FRE  @0 Animal @5 11
C03 10  X  ENG  @0 Animal @5 11
C03 10  X  SPA  @0 Animal @5 11
C03 11  X  FRE  @0 Parkinson maladie @5 12
C03 11  X  ENG  @0 Parkinson disease @5 12
C03 11  X  SPA  @0 Parkinson enfermedad @5 12
C03 12  X  FRE  @0 Rat @5 54
C03 12  X  ENG  @0 Rat @5 54
C03 12  X  SPA  @0 Rata @5 54
C07 01  X  FRE  @0 Toxine
C07 01  X  ENG  @0 Toxin
C07 01  X  SPA  @0 Toxina
C07 02  X  FRE  @0 Oestrogène @5 35
C07 02  X  ENG  @0 Estrogen @5 35
C07 02  X  SPA  @0 Estrógeno @5 35
C07 03  X  FRE  @0 Hormone stéroïde sexuelle @5 36
C07 03  X  ENG  @0 Sex steroid hormone @5 36
C07 03  X  SPA  @0 Hormona esteroide sexual @5 36
C07 04  X  FRE  @0 Hormone ovarienne @5 37
C07 04  X  ENG  @0 Ovarian hormone @5 37
C07 04  X  SPA  @0 Hormona ovárica @5 37
C07 05  X  FRE  @0 Système nerveux pathologie @5 45
C07 05  X  ENG  @0 Nervous system diseases @5 45
C07 05  X  SPA  @0 Sistema nervioso patología @5 45
C07 06  X  FRE  @0 Système nerveux central pathologie @5 46
C07 06  X  ENG  @0 Central nervous system disease @5 46
C07 06  X  SPA  @0 Sistema nervosio central patología @5 46
C07 07  X  FRE  @0 Encéphale pathologie @5 47
C07 07  X  ENG  @0 Cerebral disorder @5 47
C07 07  X  SPA  @0 Encéfalo patología @5 47
C07 08  X  FRE  @0 Extrapyramidal syndrome @5 48
C07 08  X  ENG  @0 Extrapyramidal syndrome @5 48
C07 08  X  SPA  @0 Extrapiramidal síndrome @5 48
C07 09  X  FRE  @0 Maladie dégénérative @5 49
C07 09  X  ENG  @0 Degenerative disease @5 49
C07 09  X  SPA  @0 Enfermedad degenerativa @5 49
C07 10  X  FRE  @0 Rodentia @2 NS
C07 10  X  ENG  @0 Rodentia @2 NS
C07 10  X  SPA  @0 Rodentia @2 NS
C07 11  X  FRE  @0 Mammalia @2 NS
C07 11  X  ENG  @0 Mammalia @2 NS
C07 11  X  SPA  @0 Mammalia @2 NS
C07 12  X  FRE  @0 Vertebrata @2 NS
C07 12  X  ENG  @0 Vertebrata @2 NS
C07 12  X  SPA  @0 Vertebrata @2 NS
N21       @1 169

Format Inist (serveur)

NO : PASCAL 02-0295171 INIST
ET : Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture
AU : CALLIER (Sophie); LE SAUX (Maryvonne); LHIAUBET (Anne-Marie); DI PAOLO (Thérèse); ROSTENE (William); PELAPRAT (Didier)
AF : Unité 339 INSERM. Hopital saint Antoine/Paris/France (1 aut., 2 aut., 3 aut., 5 aut., 6 aut.); Oncology and Molecular Endocrinology Research Center, Laval University Medical Center/Sainte Foy, Québec/Canada (1 aut., 4 aut.)
DT : Publication en série; Niveau analytique
SO : Journal of neurochemistry; ISSN 0022-3042; Coden JONRA9; Etats-Unis; Da. 2002; Vol. 80; No. 2; Pp. 307-316; Bibl. 1 p.3/4
LA : Anglais
EA : Recent findings suggest that gonadal steroid hormones are neuroprotective and may provide clinical benefits in delaying the development of Parkinson's disease. In this report we investigated the ability of oestradiol to protect mesencephalic dopaminergic neurones cultured in serum-free or serum-supplemented medium from toxicity induced by 6-hydroxy-dopamine or 1-methyl-4-phenylpyridinium ion (MPP+). The efficiency of both toxins and oestradiol was evaluated by tyrosine hydroxylase (TH) immunocytochemistry, [3H]dopamine ([3H]DA) uptake, length of dopaminergic processes and lactate dehydrogenase (LDH) release measurement. In cultures grown in serum-supplemented medium, a 2-h pre-treatment with high concentrations (10-100 μM) of 17β-oestradiol or 17α-oestradiol, the stereoisomer with weak oestrogenic activity, protected both dopaminergic and non-dopaminergic neurones from toxicity induced by 6-hydroxydopamine (6-OHDA; 40 or 100 μM) and by the high MPP+ concentrations (50 μM) necessary to obtain significant neuronal death under those culture conditions. At these concentrations, MPP+ was no longer selective for dopaminergic neurones but affected all cells present in the culture. In contrast, the hormonal treatments did not protect against selective degeneration of dopaminergic neurones induced by lower MPP+ concentrations (below 10 μM), related to inhibition of complex I of respiratory chain. In cultures grown in serum-free medium, oestradiol concentrations higher than 1 μM induced neuronal degeneration and no protection against 6-OHDA or MPP+ toxicity was observed at lower concentrations of the steroid. The neuroprotective effects of 17a- or 17p-oestradiol evidenced in this model might be due to the antioxidant properties of these compounds. However, other non-genomic effects of the steroids cannot be excluded.
CC : 002B02B10
FD : Mésencéphale; Neurone dopaminergique; Neurotoxine; Mort cellulaire; Neuroprotecteur; 17α-Oestradiol; 17β-Oestradiol; Antioxydant; In vitro; Animal; Parkinson maladie; Rat
FG : Toxine; Oestrogène; Hormone stéroïde sexuelle; Hormone ovarienne; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Rodentia; Mammalia; Vertebrata
ED : Midbrain; Dopaminergic neuron; Neurotoxin; Cell death; Neuroprotective agent; 17α-Estradiol; 17β-Estradiol; Antioxidant; In vitro; Animal; Parkinson disease; Rat
EG : Toxin; Estrogen; Sex steroid hormone; Ovarian hormone; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Rodentia; Mammalia; Vertebrata
SD : Mesencéfalo; Neurona dopaminérgica; Neurotoxina; Muerte celular; Neuroprotector; 17α-Estradiol; 17β-Estradiol; Antioxidante; In vitro; Animal; Parkinson enfermedad; Rata
LO : INIST-4037.354000102175200110
ID : 02-0295171

Links to Exploration step

Pascal:02-0295171

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP
<sup>+</sup>
) towards dopaminergic mesencephalic neurones in primary culture</title>
<author>
<name sortKey="Callier, Sophie" sort="Callier, Sophie" uniqKey="Callier S" first="Sophie" last="Callier">Sophie Callier</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Unité 339 INSERM. Hopital saint Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation>
<inist:fA14 i1="02">
<s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center</s1>
<s2>Sainte Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Le Saux, Maryvonne" sort="Le Saux, Maryvonne" uniqKey="Le Saux M" first="Maryvonne" last="Le Saux">Maryvonne Le Saux</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Unité 339 INSERM. Hopital saint Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Lhiaubet, Anne Marie" sort="Lhiaubet, Anne Marie" uniqKey="Lhiaubet A" first="Anne-Marie" last="Lhiaubet">Anne-Marie Lhiaubet</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Unité 339 INSERM. Hopital saint Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center</s1>
<s2>Sainte Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Rostene, William" sort="Rostene, William" uniqKey="Rostene W" first="William" last="Rostene">William Rostene</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Unité 339 INSERM. Hopital saint Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Pelaprat, Didier" sort="Pelaprat, Didier" uniqKey="Pelaprat D" first="Didier" last="Pelaprat">Didier Pelaprat</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Unité 339 INSERM. Hopital saint Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">02-0295171</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0295171 INIST</idno>
<idno type="RBID">Pascal:02-0295171</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B85</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP
<sup>+</sup>
) towards dopaminergic mesencephalic neurones in primary culture</title>
<author>
<name sortKey="Callier, Sophie" sort="Callier, Sophie" uniqKey="Callier S" first="Sophie" last="Callier">Sophie Callier</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Unité 339 INSERM. Hopital saint Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation>
<inist:fA14 i1="02">
<s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center</s1>
<s2>Sainte Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Le Saux, Maryvonne" sort="Le Saux, Maryvonne" uniqKey="Le Saux M" first="Maryvonne" last="Le Saux">Maryvonne Le Saux</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Unité 339 INSERM. Hopital saint Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Lhiaubet, Anne Marie" sort="Lhiaubet, Anne Marie" uniqKey="Lhiaubet A" first="Anne-Marie" last="Lhiaubet">Anne-Marie Lhiaubet</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Unité 339 INSERM. Hopital saint Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center</s1>
<s2>Sainte Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Rostene, William" sort="Rostene, William" uniqKey="Rostene W" first="William" last="Rostene">William Rostene</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Unité 339 INSERM. Hopital saint Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Pelaprat, Didier" sort="Pelaprat, Didier" uniqKey="Pelaprat D" first="Didier" last="Pelaprat">Didier Pelaprat</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Unité 339 INSERM. Hopital saint Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Journal of neurochemistry</title>
<title level="j" type="abbreviated">J. neurochem.</title>
<idno type="ISSN">0022-3042</idno>
<imprint>
<date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Journal of neurochemistry</title>
<title level="j" type="abbreviated">J. neurochem.</title>
<idno type="ISSN">0022-3042</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>17α-Estradiol</term>
<term>17β-Estradiol</term>
<term>Animal</term>
<term>Antioxidant</term>
<term>Cell death</term>
<term>Dopaminergic neuron</term>
<term>In vitro</term>
<term>Midbrain</term>
<term>Neuroprotective agent</term>
<term>Neurotoxin</term>
<term>Parkinson disease</term>
<term>Rat</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Mésencéphale</term>
<term>Neurone dopaminergique</term>
<term>Neurotoxine</term>
<term>Mort cellulaire</term>
<term>Neuroprotecteur</term>
<term>17α-Oestradiol</term>
<term>17β-Oestradiol</term>
<term>Antioxydant</term>
<term>In vitro</term>
<term>Animal</term>
<term>Parkinson maladie</term>
<term>Rat</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Recent findings suggest that gonadal steroid hormones are neuroprotective and may provide clinical benefits in delaying the development of Parkinson's disease. In this report we investigated the ability of oestradiol to protect mesencephalic dopaminergic neurones cultured in serum-free or serum-supplemented medium from toxicity induced by 6-hydroxy-dopamine or 1-methyl-4-phenylpyridinium ion (MPP
<sup>+</sup>
). The efficiency of both toxins and oestradiol was evaluated by tyrosine hydroxylase (TH) immunocytochemistry, [
<sup>3</sup>
H]dopamine ([
<sup>3</sup>
H]DA) uptake, length of dopaminergic processes and lactate dehydrogenase (LDH) release measurement. In cultures grown in serum-supplemented medium, a 2-h pre-treatment with high concentrations (10-100 μM) of 17β-oestradiol or 17α-oestradiol, the stereoisomer with weak oestrogenic activity, protected both dopaminergic and non-dopaminergic neurones from toxicity induced by 6-hydroxydopamine (6-OHDA; 40 or 100 μM) and by the high MPP
<sup>+</sup>
concentrations (50 μM) necessary to obtain significant neuronal death under those culture conditions. At these concentrations, MPP
<sup>+</sup>
was no longer selective for dopaminergic neurones but affected all cells present in the culture. In contrast, the hormonal treatments did not protect against selective degeneration of dopaminergic neurones induced by lower MPP
<sup>+</sup>
concentrations (below 10 μM), related to inhibition of complex I of respiratory chain. In cultures grown in serum-free medium, oestradiol concentrations higher than 1 μM induced neuronal degeneration and no protection against 6-OHDA or MPP
<sup>+</sup>
toxicity was observed at lower concentrations of the steroid. The neuroprotective effects of 17a- or 17p-oestradiol evidenced in this model might be due to the antioxidant properties of these compounds. However, other non-genomic effects of the steroids cannot be excluded.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0022-3042</s0>
</fA01>
<fA02 i1="01">
<s0>JONRA9</s0>
</fA02>
<fA03 i2="1">
<s0>J. neurochem.</s0>
</fA03>
<fA05>
<s2>80</s2>
</fA05>
<fA06>
<s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP
<sup>+</sup>
) towards dopaminergic mesencephalic neurones in primary culture</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>CALLIER (Sophie)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>LE SAUX (Maryvonne)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>LHIAUBET (Anne-Marie)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>DI PAOLO (Thérèse)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>ROSTENE (William)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>PELAPRAT (Didier)</s1>
</fA11>
<fA14 i1="01">
<s1>Unité 339 INSERM. Hopital saint Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center</s1>
<s2>Sainte Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20>
<s1>307-316</s1>
</fA20>
<fA21>
<s1>2002</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>4037</s2>
<s5>354000102175200110</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>1 p.3/4</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>02-0295171</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Journal of neurochemistry</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Recent findings suggest that gonadal steroid hormones are neuroprotective and may provide clinical benefits in delaying the development of Parkinson's disease. In this report we investigated the ability of oestradiol to protect mesencephalic dopaminergic neurones cultured in serum-free or serum-supplemented medium from toxicity induced by 6-hydroxy-dopamine or 1-methyl-4-phenylpyridinium ion (MPP
<sup>+</sup>
). The efficiency of both toxins and oestradiol was evaluated by tyrosine hydroxylase (TH) immunocytochemistry, [
<sup>3</sup>
H]dopamine ([
<sup>3</sup>
H]DA) uptake, length of dopaminergic processes and lactate dehydrogenase (LDH) release measurement. In cultures grown in serum-supplemented medium, a 2-h pre-treatment with high concentrations (10-100 μM) of 17β-oestradiol or 17α-oestradiol, the stereoisomer with weak oestrogenic activity, protected both dopaminergic and non-dopaminergic neurones from toxicity induced by 6-hydroxydopamine (6-OHDA; 40 or 100 μM) and by the high MPP
<sup>+</sup>
concentrations (50 μM) necessary to obtain significant neuronal death under those culture conditions. At these concentrations, MPP
<sup>+</sup>
was no longer selective for dopaminergic neurones but affected all cells present in the culture. In contrast, the hormonal treatments did not protect against selective degeneration of dopaminergic neurones induced by lower MPP
<sup>+</sup>
concentrations (below 10 μM), related to inhibition of complex I of respiratory chain. In cultures grown in serum-free medium, oestradiol concentrations higher than 1 μM induced neuronal degeneration and no protection against 6-OHDA or MPP
<sup>+</sup>
toxicity was observed at lower concentrations of the steroid. The neuroprotective effects of 17a- or 17p-oestradiol evidenced in this model might be due to the antioxidant properties of these compounds. However, other non-genomic effects of the steroids cannot be excluded.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B02B10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Mésencéphale</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Midbrain</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Mesencéfalo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Neurone dopaminergique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Dopaminergic neuron</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Neurona dopaminérgica</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Neurotoxine</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Neurotoxin</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Neurotoxina</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Mort cellulaire</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Cell death</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Muerte celular</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Neuroprotecteur</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Neuroprotective agent</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Neuroprotector</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>17α-Oestradiol</s0>
<s2>NK</s2>
<s5>06</s5>
<s6>«17α»-Oestradiol</s6>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>17α-Estradiol</s0>
<s2>NK</s2>
<s5>06</s5>
<s6>«17α-»Estradiol</s6>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>17α-Estradiol</s0>
<s2>NK</s2>
<s5>06</s5>
<s6>«17α»-Estradiol</s6>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>17β-Oestradiol</s0>
<s2>NK</s2>
<s5>07</s5>
<s6>«17β»-Oestradiol</s6>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>17β-Estradiol</s0>
<s2>NK</s2>
<s5>07</s5>
<s6>«17β»-Estradiol</s6>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>17β-Estradiol</s0>
<s2>NK</s2>
<s5>07</s5>
<s6>«17β»-Estradiol</s6>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Antioxydant</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Antioxidant</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Antioxidante</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>In vitro</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>In vitro</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>In vitro</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Animal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Animal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Animal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Parkinson maladie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Rat</s0>
<s5>54</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Rat</s0>
<s5>54</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Rata</s0>
<s5>54</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Toxine</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Toxin</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Toxina</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Oestrogène</s0>
<s5>35</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Estrogen</s0>
<s5>35</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Estrógeno</s0>
<s5>35</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Hormone stéroïde sexuelle</s0>
<s5>36</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Sex steroid hormone</s0>
<s5>36</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Hormona esteroide sexual</s0>
<s5>36</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Hormone ovarienne</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Ovarian hormone</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Hormona ovárica</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>45</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Système nerveux central pathologie</s0>
<s5>46</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>46</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Encéphale pathologie</s0>
<s5>47</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>47</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>47</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Extrapyramidal syndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>49</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>49</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>49</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE">
<s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="10" i2="X" l="ENG">
<s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="10" i2="X" l="SPA">
<s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="11" i2="X" l="FRE">
<s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="11" i2="X" l="ENG">
<s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="11" i2="X" l="SPA">
<s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="12" i2="X" l="FRE">
<s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="12" i2="X" l="ENG">
<s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="12" i2="X" l="SPA">
<s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21>
<s1>169</s1>
</fN21>
</pA>
</standard>
<server>
<NO>PASCAL 02-0295171 INIST</NO>
<ET>Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP
<sup>+</sup>
) towards dopaminergic mesencephalic neurones in primary culture</ET>
<AU>CALLIER (Sophie); LE SAUX (Maryvonne); LHIAUBET (Anne-Marie); DI PAOLO (Thérèse); ROSTENE (William); PELAPRAT (Didier)</AU>
<AF>Unité 339 INSERM. Hopital saint Antoine/Paris/France (1 aut., 2 aut., 3 aut., 5 aut., 6 aut.); Oncology and Molecular Endocrinology Research Center, Laval University Medical Center/Sainte Foy, Québec/Canada (1 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of neurochemistry; ISSN 0022-3042; Coden JONRA9; Etats-Unis; Da. 2002; Vol. 80; No. 2; Pp. 307-316; Bibl. 1 p.3/4</SO>
<LA>Anglais</LA>
<EA>Recent findings suggest that gonadal steroid hormones are neuroprotective and may provide clinical benefits in delaying the development of Parkinson's disease. In this report we investigated the ability of oestradiol to protect mesencephalic dopaminergic neurones cultured in serum-free or serum-supplemented medium from toxicity induced by 6-hydroxy-dopamine or 1-methyl-4-phenylpyridinium ion (MPP
<sup>+</sup>
). The efficiency of both toxins and oestradiol was evaluated by tyrosine hydroxylase (TH) immunocytochemistry, [
<sup>3</sup>
H]dopamine ([
<sup>3</sup>
H]DA) uptake, length of dopaminergic processes and lactate dehydrogenase (LDH) release measurement. In cultures grown in serum-supplemented medium, a 2-h pre-treatment with high concentrations (10-100 μM) of 17β-oestradiol or 17α-oestradiol, the stereoisomer with weak oestrogenic activity, protected both dopaminergic and non-dopaminergic neurones from toxicity induced by 6-hydroxydopamine (6-OHDA; 40 or 100 μM) and by the high MPP
<sup>+</sup>
concentrations (50 μM) necessary to obtain significant neuronal death under those culture conditions. At these concentrations, MPP
<sup>+</sup>
was no longer selective for dopaminergic neurones but affected all cells present in the culture. In contrast, the hormonal treatments did not protect against selective degeneration of dopaminergic neurones induced by lower MPP
<sup>+</sup>
concentrations (below 10 μM), related to inhibition of complex I of respiratory chain. In cultures grown in serum-free medium, oestradiol concentrations higher than 1 μM induced neuronal degeneration and no protection against 6-OHDA or MPP
<sup>+</sup>
toxicity was observed at lower concentrations of the steroid. The neuroprotective effects of 17a- or 17p-oestradiol evidenced in this model might be due to the antioxidant properties of these compounds. However, other non-genomic effects of the steroids cannot be excluded.</EA>
<CC>002B02B10</CC>
<FD>Mésencéphale; Neurone dopaminergique; Neurotoxine; Mort cellulaire; Neuroprotecteur; 17α-Oestradiol; 17β-Oestradiol; Antioxydant; In vitro; Animal; Parkinson maladie; Rat</FD>
<FG>Toxine; Oestrogène; Hormone stéroïde sexuelle; Hormone ovarienne; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Rodentia; Mammalia; Vertebrata</FG>
<ED>Midbrain; Dopaminergic neuron; Neurotoxin; Cell death; Neuroprotective agent; 17α-Estradiol; 17β-Estradiol; Antioxidant; In vitro; Animal; Parkinson disease; Rat</ED>
<EG>Toxin; Estrogen; Sex steroid hormone; Ovarian hormone; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Rodentia; Mammalia; Vertebrata</EG>
<SD>Mesencéfalo; Neurona dopaminérgica; Neurotoxina; Muerte celular; Neuroprotector; 17α-Estradiol; 17β-Estradiol; Antioxidante; In vitro; Animal; Parkinson enfermedad; Rata</SD>
<LO>INIST-4037.354000102175200110</LO>
<ID>02-0295171</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B85 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000B85 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0295171
   |texte=   Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022